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Abstract 
Investigation of possible candidates for epilepsy surgery will usually require inpatient EEG to 
capture seizures and allow full operative planning. Withdrawal of antiepileptic drugs increases the 
yield of this valuable diagnostic information and the benefits of this should justify any increase in the 
risk of harm associated with these seizures. We propose an algorithm for enhancing the safety of AED 
withdrawal in VT admissions while ensuring adequate seizure yields. This algorithm is accompanied 
by a table which allows utilisation about the knowledge of the clinical and pharmacological 




This document outlines proposed best practice for management of antiepileptic drug  (AED) dosing 
when patients are admitted for monitoring of seizures to an epilepsy monitoring unit (EMU). In the 
vast majority of cases EMU admissions are safe and, even if seizures occur, will pass off without 
complication. Previous guidance has concentrated on ensuring practice around technical aspects of 
EEG monitoring itself and staffing within the unit. In this guidance we aim to outline optimally safe 
ways of ensuring that EMUs ensure the minimisation of risk to the patients admitted under their 
care. Risk minimisation requires 
i) management of drug reduction,  
ii) provision of adequate rescue medication, and  
iii) provision of adequate supervision to allow rapid response to generalised seizures.  
 
A table is provided to help plan AED drug withdrawal to ensure that any change in AED effect is 
timely and safe, taking into account the pharmacological properties of the AEDs in question, and the 




Admissions to epilepsy monitoring units (EMUs) are a necessary part of the diagnostic and investigative 
process of most modern epilepsy centres. Video Telemetry (VT) utilises simultaneous video and EEG to 
capture episodic events for a variety of indications, including the diagnosis of transient episodes of 
uncertain nature (especially to distinguish epileptic from non-epileptic attack disorder); the classification 
of epilepsy syndrome; and pre-surgical evaluation in patients with medically refractory epilepsy 1.  
This paper discusses the evidence for best practice in managing AED prescribing in patients in patients 
with epilepsy, where the purpose of admission is recording epileptic seizures in order to localize their 
onset. The suggestions made are specifically formulated more for patients with epilepsy than Non-
Epileptic Attack Disorder, where AEDs will more likely be stopped altogether to confirm a diagnosis of 
Nonepileptic seizures.  
In patients undergoing pre-surgical evaluation to localize the seizure-onset zone, it is helpful to  
record as many events as possible in the allotted time. The number required depends both on the 
quality of the video and EEG recording for each episode, and the pre-test probability that the events 
are unifocal in origin2.  
AED withdrawal increases the probability of recording seizures during a pre-defined duration of 
admission, so helping to reduce the length of stay3; 4. Failure to record adequate seizures has negative 
consequences for the individual patient; it may prevent a patient from accessing epilepsy surgery, or 
may precipitate repeated admissions, so prolonging the length of the surgical workup period. 
Repeated hospital admissions are inconvenient to patients, may result in loss of earnings, be anxiety-
provoking, and may require multiple periods of drug withdrawal, thus adding to the burden of 
disease. What is more, EMU admissions are expensive, requiring multi-day assessments with 
intensive monitoring, and clinician and physiologist time to interpret prolonged EEG recordings. 
Admissions to the EMU carry a small but measurable degree of risk. The MORTEMUS study 5 
estimated the incidence of sudden unexpected death in epilepsy (SUDEP) in patients undergoing VT 
to be 1.2 per 10,000 video telemetry recordings (5.1/1,000 patient years). A recent meta-analysis 
found around 7% of admissions to the EMU resulted in an adverse event 6, and a UK-based national 
service evaluation also found that 7% of seizures in the EMU were associated with an adverse event 
7. The most common adverse events reported were status epilepticus (1.5%), postictal psychosis 
(1.8%), and cardiorespiratory complications (0.04%), falls (1.3%) and seizure related injuries (0.5%) 
6. Such injuries may be severe, such as vertebral compression fractures (11% of patients with a GTCS 
in one study) 8, or epidural haematoma requiring emergency evacuation, following a seizure-related 
fall 9. 
AED withdrawal in patients undergoing surgical evaluation may not always lend itself to a protocol-
driven approach. The number of patient and seizure variables, possible drug combinations, 
pharmacokinetic factors, and drug interactions that need to be considered in each case complicates 
the algorithm. A consensus-based recommendation concluded that AED reduction should be 
individualized to consider both drug- and patient-related factors 10. AED withdrawal procedures also 
need to take into account the different admission protocols across EMUs; whether admissions are for 
planned duration or for a planned number of attacks.  
Rate, timing, and supervision of drug withdrawal also vary. Some EMUs have the facility for an 
inpatient supervised pre-monitoring to withdraw medication. Supervision levels vary between 
EMUs11 and those with lower nurse:patient ratios, or without 24-hour observation would need to 
exercise a higher level of caution in AED withdrawal. 
This paper aims to provide practical information to help guide these complex clinical decisions, 
particularly regarding the pharmacokinetic properties of, and interactions between, AEDs. 
We recognise the need to optimise both the safety and the effectiveness of EMU admissions, and 
would highlight the requirement to understand and take into account the pharmacokinetic 
properties of each individual’s AED regime. We   
 
The effect of AED withdrawal on EMUs 
 
Adverse events vs efficacy 
Several studies have reported a medication taper protocol for VT8; 12; 13; 14, in some cases comparing 
seizure yield and adverse effects from slower and faster rates of withdrawal15; 16; 17. The majority 
have an observational design, and variation in patient population and drug regimes make it difficult 
to draw any inferences about the utility and safety of different rates of medication withdrawal from 
these studies. These studies are underpowered to detect differences in safety measures between 
different taper protocols, although Guld et al. found that patients who completely withdrew from 
AEDs had a significantly higher rate of GTCS (52.2% vs 18.2%, p=0.002)16.  
Speed and timing of AED withdrawal 
Very rapid drug withdrawal alongside sleep deprivation has been examined. Rizvi et al reported a 
diagnostic yield of 90.5%, with a low adverse event profile, although lorazepam was required in 60% 
of patients to abort seizure clusters18. Slow AED withdrawal (<30%/ day) in surgical candidates 
recorded seizures in only 43% of19 admissions15. An EMU in the Netherlands described their 
experience of withdrawing AEDs at home, up to 4 weeks prior to the admission for VT, depending on 
the half-life of the AED. During the subsequent 5-day admission, 84% of patients recorded sufficient 
seizure numbers with only 1.7% of patients having status epilepticus during their hospital 
admission20.  In Denmark, an EMU with a non-restrictive setting, in which patients are not confined 
to bed, recorded no injuries in 976 consecutive patients despite AED withdrawal21.  
A controlled trial of AED withdrawal regimes22 randomly allocated 140 patients to have AEDs 
withdrawn sequentially at a rate of 15-30%/ day (slow arm), or >30%/day (rapid arm). Patients in 
the rapid titration group had a shorter time to first seizure (2.0 +/-1.7 vs 4.6 +/-3.0) and shorter 
admission (4.7+/-2.6 days vs 6.6+/-3.5 days in the slow arm), but a higher rate of 4-hour seizure 
clusters. Interestingly, both arms eventually achieved the same mean reduction in medication (68.3% 
+/- 28% reduction compared to baseline), in order to achieve an adequate recording.  
 
Localisation of the seizure onset and irritative zones 
There is substantial evidence that AED withdrawal affects seizure propagation, rather than the 
seizure onset characteristics, as determined by semiology and EEG. This appears to hold true even 
when AED withdrawal is associated with increased seizure frequency, secondary generalization and 
clustering4; 19; 23; 24; 25. One study3 suggested that AED withdrawal, while changing the interictal EEG, 
continues to localise ictal EEG to the seizure onset zone and lesional zone. 
 
Current practice and guidelines for AED withdrawal 
 
Audits of EMUs in Europe and the USA have shown a wide variation in the way that units deal with 
AED withdrawal and the provision of rescue medication, with many units lacking standardised 
precautions (see table 1).  Considerable work has gone into outlining best protocols for staffing and 
nursing cover, seizure detection and on the specific technical requirements for the EEG itself10; 26; 27, 
but there has been no specific guidance on AED manipulation, despite the recognised risk of adverse 
events. A large national cluster-randomized study is currently underway in France, to assess the 
effect of a standardized protocol versus current practice28. 
Observational studies looking at AED withdrawal regimes face the challenge of describing and 
analysing highly variable processes. They include patients taking between 1 and 6 AEDs, in up to 59 
different combinations15; 22; 29. Reductions are often described as a percentage, but it is not always 
explicit whether each AED should be reduced simultaneously or sequentially. Furthermore, not all 
AEDs are associated with linear dose/concentration relationships, further complicating the 
interpretation of drug reductions expressed in percentage terms. In the RCT of rapid vs slow AED 
withdrawal22, rapid withdrawal was considered 30-50% daily reduction, while slow taper was 
considered 15-<30% daily reduction, of sequential AEDs. A consensus-based guideline10 concluded 
that ‘plans to withdraw AEDs should be individualized to consider patient- and drug-specific factors 
in relation to need to capture events’, and that ‘each patient should have an individualized plan for 
managing acute seizures’. It was indicated that discontinuation of AEDs prior to admission ‘should be 
considered only in exceptional circumstances’. The workshop noted that where drug reduction is 
needed, the usual practice of most units is to reduce AEDs by 50% on day 1 and 75% on day 2, and to 
tailor further reduction, stopping one or all AEDs, until the desired number of events are recorded 11. 
 
Recommendations for safe practice 
1) Determining whether or not AEDs should be reduced - Assessment of 
seizures and risk for individual patient 
 
Based on the evidence presented above, and published consensus guidelines, we would propose 
that clinicians admitting patients to the VTU take into account a range of factors in considering 
whether AEDs should be withdrawn or reduced. These are summarised in the algorithm in figure 
1. 
 
The patient’s risk factors for sustaining harm during a seizure should be assessed and 
considered prior to considering AED withdrawal.  Factors shown to be associated with 
increased risk of adverse events during VT include advanced age, long duration of epilepsy, 
previous history of psychiatric illness, history of seizure-related injuries or status 
epilepticus9, and the presence of osteopaenia8. The patient’s usual seizure types should be 
assessed, and clear seizure descriptions recorded prior to admission (particularly with 
regard to history of GTCS), alongside a record of the patient’s recent habitual seizure rate. 
 
There will usually be no need to reduce medications if a patient has frequent seizures 
(>2/week), depending on the length of the planned admission. If the patient is at high risk, 
such as a history of SE, consideration should be given to performing monitoring without 
medication reduction. In such cases the need for implementing a plan for rescue medication 
is even greater. 
At the time of admission, each patient should have rescue medication prescribed, with clear 
instructions a to when this prescription should take effect (perhaps clarifying number, type, 
or duration of seizures that would trigger the plan). The rescue medication will vary, but will 
usually involve some reinstatement of the patient’s previous treatment, (e.g. part or full daily 
dose of baseline medication) with or without additional benzodiazepine. 
2) Consent 
The risks and benefits of video telemetry with or without AED withdrawal should be 
discussed with each patient prior to admission, and written informed consent obtained.  
 
3) AED withdrawal regime  
Where seizures are relatively infrequent, the risk assessment does not raise significant 
concerns, and the patient has given consent to medication withdrawal, the physician needs to 
consider the best strategy for reducing the doses of AEDs. This strategy should take account 
of a number of factors, particularly drug half-life, duration of pharmacological effect, and 
tendency to mutual pharmacokinetic interactions. Where available, experience from the 
patient’s previous episodes of VT may also be informative, as may prior knowledge of which 
AED is most effective in that patient.  
We have drawn up the Patsalos Table (table 2), which summarises the pharmacokinetic 
properties and interactions of AEDs, to inform decisions about medication withdrawal. AEDs 
have been grouped into 6 categories:  
 
Category 1 are those AEDs where there is concern about an association with withdrawal 
seizures (benzodiazepines or barbiturates). Reduction of these medications tends to be 
handled more carefully, despite a lack of direct evidence to confirm this30 ( 
 
Category 2 are those with a very long elimination half-life, which may require effective pre-
admission withdrawal to effect changes in admission concentrations (perampanel and 
zonisamide);  
Category 3 have an intermediate half-life, and can usually be stopped abruptly, early in the 
admission, in order to achieve an adequate reduction in serum levels within a reasonable 
time frame;  
Category 4 are those with a short half life, in which graded reduction is recommended in 
order to prevent a precipitous drop in serum levels;  
Category 5 are those where the antiseizure effect is unrelated to serum levels (valproate and 
vigabatrin). The clinical effect of these drugs persists even once the drug has been cleared 
from the serum (ie their biological half-life is prolonged), and these drugs may need to be 
withdrawn earlier than their half-life would suggest.  
Category 6 are those (phenytoin and stiripentol) which display non-linear (zero-order or 
saturation) kinetics. As the rate of metabolism is close to the maximum capacity of the 
enzymes involved in their breakdown, a small adjustment in the dose of the drug may lead to 
a disproportionately large change in their serum concentration. 
Polypharmacy poses more complex problems. Mutual interaction between AEDs will affect 
the decisions around drug withdrawal. Reduction in enzyme-inducing AEDs (eg 
carbamazepine, phenytoin) may increase levels of accompanying AEDs, whereas withdrawal 
of enzyme inhibiting AEDs (eg Valproate) may led to a drop in accompanying AEDs. Such 
interactions should be anticipated and adjustments made while taking these into account. 
Particularly where VT admissions last for days, we would see little utility in routinely 
measuring serum AED levels.  
4) Documentation of medication reduction plan and review 
The plan for reducing AED dose should be clearly documented prior to admission. Patients 
should be reviewed by medical staff on a daily basis, and any necessary adjustments made on 
the basis of seizure frequency. It is important for medical staff to liaise with the 
neurophysiology department before making decisions about medication changes, to 
determine whether events have occurred that are unreported by the patient, and to decide 
whether reported events are the patient’s habitual events / events of interest, and whether 
the EEG recorded is adequate. 
5) Prescription of rescue medication 
On admission, a prescription should be put in place for rescue medication to be given if 
seizures worsen. Nursing and medical staff should be aware (or have information easily to 
hand) of the predefined conditions of administration, the dose, and intended timing of any 
rescue medication. This prescription may consist of  
a) A benzodiazepine (iv lorazepam or buccal midazolam) 
b) A full daily dose of some or all of the withdrawn drugs 
6) Reintroduction of medications 
If AEDs have been withheld for up to 3-4 days, hepatic enzyme activity and serum levels 
would suggest that it would be safe to reinstate the medication at the full dose31. We would 
suggest a standard period of observation of between 12 and 24 hours after AED therapy has 
been reinstated while treatment is stabilised, with consideration potentially being given to 
provision of benzodiazepine rescue medication11.  
7) Audit of practice 
Each unit should undertake audits on a regular basis – preferably every 1-2 years to ensure 
that the rate of provocation of generalised seizures, the staff response times, and the 




AED withdrawal in the EMU increases the probability of seizures occurring, but this cannot be done 
without also increasing seizure propagation and therefore the risk of generalized and/ or severe or 
prolonged seizures, and the associated risk of harm. Much work has been done in recent years to 
address the risk of harm from seizures in the EMU, particularly with respect to nursing care, and 
levels of supervision, but the nature of generalised tonic clonic seizures is such that this risk will 
never be eliminated entirely.  A conservative approach could be proposed with serial admissions 
having an increasingly proactive approach to medication reduction. However, such risk avoidance 
must be balanced against the risk of delaying specific intervention in those who would benefit from 
it.  
Decisions regarding AED withdrawal are a delicate balance of risk vs benefit, and are complicated by 
the number of patient, seizure, and medication variables that need to be taken into account. A 
detailed understanding of the pharmacokinetics of antiepileptic medications and their interactions, 
and an up-to-date knowledge of the evidence base surrounding withdrawal of AEDs will help to 





Table 1: Recent audits of practice in the EMU 
Study Bulow Rubboli  Kouboulashvili Hamandi 
Year 2008 2015 2016 2017 
Location USA Europe Europe UK 
Standardized protocol for preadmission screening 
(seizure frequency/ severity) 
Not stated 56% Not stated 64% 
Withdrawal of medication prior to admission 59% Not stated 52% Not stated 
Protocol for speed of medication withdrawal 20% Not stated 15% 36% 
Signed informed consent for recording  65%  83% 56% 72% (only 48% 
included AED reduction 
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12-46 None None None  
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None NB withdrawal of PHB may increase concomitant 
systemic medications:  
Category 2 
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Figure 1 – Algorithm for AED Withdrawal in VT Monitoring Unit 
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